CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), sometimes called a GRF analogue. It is classed as a growth hormone secretagogue because it is studied for its ability to stimulate the body's own release of growth hormone.

What does research suggest about CJC-1295?

Preclinical studies have documented effects on the growth-hormone axis in animal models, and there is a limited early clinical history. Overall human evidence is limited, and no well-powered trials have established it as an effective therapy for any use.

Is CJC-1295 approved or legal?

CJC-1295 is not an approved medicine for general use and is best described as having research chemical status. Its regulatory and legal position varies by country, and it is not authorised as a treatment.

Its long-term safety in humans has not been established through rigorous research. Because it acts on a hormonal pathway, it carries real risks, and it should not be regarded as a validated or proven therapy.

What are the reported side effects of CJC-1295?

Reported effects include injection-site reactions and water retention. Because it influences the growth-hormone axis, other systemic effects are possible, and the full safety profile is not well characterised.

How does CJC-1295 relate to Ipamorelin?

CJC-1295 is often discussed alongside Ipamorelin because both are growth hormone secretagogues that act on the growth-hormone axis through different but complementary mechanisms. This pairing is a common topic in research discussion, not an endorsement of use.

What is the difference between CJC-1295 "with DAC" and "without DAC"?

These labels refer to two versions discussed in research circles. The "with DAC" form incorporates a drug-affinity-complex element intended to bind to blood albumin and extend how long the molecule stays active, whereas the "without DAC" form (often equated with modified GRF 1-29) lacks that albumin-binding component and is described as much shorter-acting. The distinction is a frequent source of confusion because the same name gets applied to both. This is background information, not guidance for use.

Why is CJC-1295 so often mentioned together with Ipamorelin?

The two are commonly paired in online discussion because they act on the growth-hormone axis through different mechanisms: CJC-1295 is a GHRH analogue, while Ipamorelin belongs to a separate class (a growth-hormone secretagogue that acts on the ghrelin/GHS pathway). People discuss combining complementary mechanisms, but this pairing is a discussion pattern rather than a validated or approved therapy, and it carries the same lack of clinical support and safety data noted throughout this page.

Is CJC-1295 the same thing as a growth-hormone-releasing hormone found in the body?

No. A common misconception is that it is simply "natural GHRH." It is a synthetic analogue whose sequence has been deliberately modified to resist rapid breakdown and, in the DAC version, to persist far longer than the body's own short-lived GHRH. Those modifications change its behaviour, which is one reason its effects and risks cannot be assumed to match natural hormone signalling.

Where can I buy CJC-1295 and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Growth Hormone Secretagogue

Buy CJC-1295 – Vendors, Prices, Testing and Evidence

Buy CJC-1295

Also known as: GRF analogue

Evidence grade C — Early / PreclinicalRisk flag

Short answer

A growth-hormone-releasing factor analogue, often discussed alongside Ipamorelin. Limited human evidence.

Where can you buy CJC-1295?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH).

What is not established?

Limited early clinical history; not an approved therapy.

Safety

Hormonal effects carry real risks; not a validated therapy.

Regulatory status

Not an approved medicine for general use. Research chemical status.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy CJC-1295: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	CJC-1295 research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

CJC-1295 research product

Code PEPTIDES10 −10% · discount code details

What is it?

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH).

Research and evidence

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), the signalling molecule the body uses to prompt the pituitary gland to release growth hormone. Because it mirrors the structure of the natural GHRH fragment, it is sometimes referred to as a GRF analogue and is grouped among the compounds known as growth hormone secretagogues. In research discussion it is frequently paired with related peptides such as Ipamorelin. The central premise behind its study is stimulation of the body's own growth-hormone axis, rather than direct administration of growth hormone itself. It is important to state clearly at the outset that CJC-1295 is not an approved medicine for general use and is best characterised as a research chemical.

The evidence picture for CJC-1295 is limited and should be read cautiously. Preclinical work has documented effects on the growth-hormone axis in animal models, and the compound carries a limited early clinical history. That history, however, has not translated into approval as a therapy for any indication, and robust, large-scale human outcome data are lacking. On our evidence scale it sits at a low tier, reflecting that most of what is known derives from mechanistic reasoning and preliminary studies rather than from well-powered clinical trials establishing safety and efficacy in people. Marketing-style claims that frame CJC-1295 as a proven treatment for recovery, body composition, or anti-ageing run well ahead of what the published research actually supports.

Because CJC-1295 acts on a hormonal pathway, any use carries real and not fully characterised risks. Reported effects in the available literature and user discussion include injection-site reactions and water retention, and manipulating the growth-hormone axis has broader systemic implications that are not trivial. Long-term safety in humans has not been established through rigorous study. This page is an educational reference intended to summarise what is and is not known; it is not medical advice, does not endorse use, and does not provide dosing or sourcing guidance. Anyone considering questions about growth-hormone physiology or hormonal compounds should consult a qualified medical professional.

Evidence grade: C

Limited early clinical history; not an approved therapy. Preclinical GH-axis effects documented.

Human evidence

Limited early clinical history; not an approved therapy.

Animal and preclinical evidence

Preclinical GH-axis effects documented.

Proposed mechanisms

Stimulation of endogenous growth-hormone release

Safety concerns and known side effects

Hormonal effects carry real risks; not a validated therapy.

Injection-site reactions reported
Water retention reported

Regulatory status

Not an approved medicine for general use. Research chemical status.

CJC-1295 research timeline

1982
Growth-hormone-releasing hormone (GHRH) is isolated and characterised, establishing the biological target that later GHRH analogues, including CJC-1295, are designed to mimic.
Early 2000s
The Canadian biotech ConjuChem develops CJC-1295 as a modified GHRH(1-29) analogue, using a drug-affinity-complex (DAC) approach intended to bind albumin and extend the peptide's action beyond that of native GHRH.
Mid-2000s
Early-phase human pharmacology work reports that a single administration can produce prolonged elevations in growth hormone and IGF-1, generating interest in the compound's extended activity.
Late 2000s
Clinical development does not advance to marketing approval, and the compound remains investigational rather than becoming a licensed medicine.
2010s
Anti-doping authorities classify GHRH analogues such as CJC-1295 as prohibited substances in sport, and the compound spreads through the unregulated research-chemical market, frequently discussed alongside Ipamorelin.
Early 2020s
Regulators continue to treat CJC-1295 as an unapproved substance, and it does not appear on sanctioned compounding lists in major jurisdictions.

Frequently asked questions about CJC-1295

What is CJC-1295?: CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), sometimes called a GRF analogue. It is classed as a growth hormone secretagogue because it is studied for its ability to stimulate the body's own release of growth hormone.
What does research suggest about CJC-1295?: Preclinical studies have documented effects on the growth-hormone axis in animal models, and there is a limited early clinical history. Overall human evidence is limited, and no well-powered trials have established it as an effective therapy for any use.
Is CJC-1295 approved or legal?: CJC-1295 is not an approved medicine for general use and is best described as having research chemical status. Its regulatory and legal position varies by country, and it is not authorised as a treatment.
Is CJC-1295 safe?: Its long-term safety in humans has not been established through rigorous research. Because it acts on a hormonal pathway, it carries real risks, and it should not be regarded as a validated or proven therapy.
What are the reported side effects of CJC-1295?: Reported effects include injection-site reactions and water retention. Because it influences the growth-hormone axis, other systemic effects are possible, and the full safety profile is not well characterised.
How does CJC-1295 relate to Ipamorelin?: CJC-1295 is often discussed alongside Ipamorelin because both are growth hormone secretagogues that act on the growth-hormone axis through different but complementary mechanisms. This pairing is a common topic in research discussion, not an endorsement of use.
What is the difference between CJC-1295 "with DAC" and "without DAC"?: These labels refer to two versions discussed in research circles. The "with DAC" form incorporates a drug-affinity-complex element intended to bind to blood albumin and extend how long the molecule stays active, whereas the "without DAC" form (often equated with modified GRF 1-29) lacks that albumin-binding component and is described as much shorter-acting. The distinction is a frequent source of confusion because the same name gets applied to both. This is background information, not guidance for use.
Why is CJC-1295 so often mentioned together with Ipamorelin?: The two are commonly paired in online discussion because they act on the growth-hormone axis through different mechanisms: CJC-1295 is a GHRH analogue, while Ipamorelin belongs to a separate class (a growth-hormone secretagogue that acts on the ghrelin/GHS pathway). People discuss combining complementary mechanisms, but this pairing is a discussion pattern rather than a validated or approved therapy, and it carries the same lack of clinical support and safety data noted throughout this page.
Is CJC-1295 the same thing as a growth-hormone-releasing hormone found in the body?: No. A common misconception is that it is simply "natural GHRH." It is a synthetic analogue whose sequence has been deliberately modified to resist rapid breakdown and, in the DAC version, to persist far longer than the body's own short-lived GHRH. Those modifications change its behaviour, which is one reason its effects and risks cannot be assumed to match natural hormone signalling.
Where can I buy CJC-1295 and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

GH axisRecovery

Compare CJC-1295

CJC-1295 vs Ipamorelin CJC-1295 vs Sermorelin

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10